EP3755690A4 - Inhibiteurs d'egfr et leurs procédés d'utilisation - Google Patents

Inhibiteurs d'egfr et leurs procédés d'utilisation Download PDF

Info

Publication number
EP3755690A4
EP3755690A4 EP19758285.1A EP19758285A EP3755690A4 EP 3755690 A4 EP3755690 A4 EP 3755690A4 EP 19758285 A EP19758285 A EP 19758285A EP 3755690 A4 EP3755690 A4 EP 3755690A4
Authority
EP
European Patent Office
Prior art keywords
egfr
inhibitors
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19758285.1A
Other languages
German (de)
English (en)
Other versions
EP3755690A1 (fr
Inventor
Nathanael S. Gray
Dries DE CLERCQ
Jaebong Jang
Pasi Janne
Ciric TO
Michael Eck
Eunyoung Park
David HEPPNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP3755690A1 publication Critical patent/EP3755690A1/fr
Publication of EP3755690A4 publication Critical patent/EP3755690A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP19758285.1A 2018-02-20 2019-02-20 Inhibiteurs d'egfr et leurs procédés d'utilisation Withdrawn EP3755690A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632819P 2018-02-20 2018-02-20
US201862744086P 2018-10-10 2018-10-10
PCT/US2019/018773 WO2019164948A1 (fr) 2018-02-20 2019-02-20 Inhibiteurs d'egfr et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3755690A1 EP3755690A1 (fr) 2020-12-30
EP3755690A4 true EP3755690A4 (fr) 2021-10-27

Family

ID=67687390

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19758285.1A Withdrawn EP3755690A4 (fr) 2018-02-20 2019-02-20 Inhibiteurs d'egfr et leurs procédés d'utilisation

Country Status (6)

Country Link
US (1) US20200390783A1 (fr)
EP (1) EP3755690A4 (fr)
JP (1) JP2021514400A (fr)
AU (1) AU2019225806A1 (fr)
CA (1) CA3087288A1 (fr)
WO (1) WO2019164948A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164947A1 (fr) 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de l'egfr et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124399A1 (fr) * 2008-04-11 2009-10-15 Thallion Pharmaceuticals Inc. Inhibition de la migration cellulaire par une dibenzodiazépinone farnésylée
WO2017024317A2 (fr) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles
WO2017185023A1 (fr) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Dégradation de la kinase 9 cycline-dépendante (cdk9) par conjugaison d'inhibiteurs de cdk9 avec un ligand de type ligase e3 et leurs procédés d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254159A1 (en) * 2003-02-27 2004-12-16 Hasvold Lisa A. Heterocyclic kinase inhibitors
WO2006061126A2 (fr) * 2004-12-09 2006-06-15 F. Hoffmann-La Roche Ag Derives de dibenzoxazepinone
WO2007056388A2 (fr) * 2005-11-07 2007-05-18 The General Hospital Corporation Compositions et procédés de modulation de l’activité de la poly(adp-ribose) polymérase
RU2016116516A (ru) * 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
JP5908728B2 (ja) * 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
WO2012045194A1 (fr) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazépinones à titre d'inhibiteurs de fak pour le traitement du cancer
WO2014160430A1 (fr) * 2013-03-13 2014-10-02 Georgetown University Petites molécules inhibitrices d'erk5 et de lrrk2
WO2015196072A2 (fr) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Utilisations d'inhibiteurs de kinase pour l'induction et le maintien de la pluripotence
CA3020172A1 (fr) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Composes pyrimido-diazepinone d'echafaudage de kinase et procedes de traitement de troubles induits par pi3k
WO2019164947A1 (fr) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de l'egfr et leurs procédés d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124399A1 (fr) * 2008-04-11 2009-10-15 Thallion Pharmaceuticals Inc. Inhibition de la migration cellulaire par une dibenzodiazépinone farnésylée
WO2017024317A2 (fr) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles
WO2017185023A1 (fr) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Dégradation de la kinase 9 cycline-dépendante (cdk9) par conjugaison d'inhibiteurs de cdk9 avec un ligand de type ligase e3 et leurs procédés d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASTALERZ ET AL: "Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases", 27 April 2007, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, PAGE(S) 2828 - 2833, ISSN: 0960-894X, XP022049596 *
See also references of WO2019164948A1 *

Also Published As

Publication number Publication date
JP2021514400A (ja) 2021-06-10
EP3755690A1 (fr) 2020-12-30
WO2019164948A1 (fr) 2019-08-29
CA3087288A1 (fr) 2019-08-29
US20200390783A1 (en) 2020-12-17
AU2019225806A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
EP3684361A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3676267A4 (fr) Inhibiteurs d'egfr et/ou de her2 et procédés d'utilisation
EP3743063A4 (fr) Inhibiteurs de cbl-b et leurs procédés d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3810617A4 (fr) Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation
EP3558998A4 (fr) Inhibiteurs d'éctonucléotidase et leurs méthodes d'utilisation
EP3802489A4 (fr) Inhibiteurs de masp -2 et procédés d'utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3710430A4 (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
EP3983386A4 (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3755337A4 (fr) Combinaisons pharmaceutiques d'inhibiteurs d'egfr et leurs procédés d'utilisation
EP3765006A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
EP3986894A4 (fr) Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation
EP3886853A4 (fr) Composés diarylhydantoine et leurs procédés d'utilisation
EP3810615A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
EP4058015A4 (fr) Inhibiteurs allostériques d'egfr et leurs procédés d'utilisation
EP3728268A4 (fr) Inhibiteurs de nek et procédés d'utilisation
EP3897622A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
EP3755697A4 (fr) Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci
EP3678660A4 (fr) Inhibiteurs de trpc5 et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20210928

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20210922BHEP

Ipc: A61K 31/5513 20060101ALI20210922BHEP

Ipc: C07D 403/10 20060101ALI20210922BHEP

Ipc: C07D 243/08 20060101ALI20210922BHEP

Ipc: C07D 403/04 20060101ALI20210922BHEP

Ipc: C07D 243/38 20060101AFI20210922BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20220714